{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:23:19Z","timestamp":1783426999986,"version":"3.54.6"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,7]]},"DOI":"10.7759\/cureus.112202","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:06:09Z","timestamp":1783425969000},"source":"Crossref","is-referenced-by-count":0,"title":["A Systematic Literature Review of Emerging Advances in Neurological Disorders: Diagnostic Innovations, Therapeutic Strategies, and Future Directions"],"prefix":"10.7759","author":[{"given":"V V Siva","family":"Ramireddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja Gulfam","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha R","family":"Pednekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chhaya Trimbakrao","family":"Munde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketki","family":"Wagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/s24165143","article-title":"Innovations in biosensor technologies for healthcare diagnostics and therapeutic drug monitoring: applications, recent progress, and future research challenges","volume":"24","author":"Hemdan M","year":"2024","unstructured":"Hemdan M, Ali MA, Doghish AS, et al.. Innovations in biosensor technologies for healthcare diagnostics and therapeutic drug monitoring: applications, recent progress, and future research challenges. Sensors (Basel). 2024, 24:5143. 10.3390\/s24165143","journal-title":"Sensors (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12220-8","article-title":"Artificial intelligence in neurology: opportunities, challenges, and policy implications","volume":"271","author":"Voigtlaender S","year":"2024","unstructured":"Voigtlaender S, Pawelczyk J, Geiger M, et al.. Artificial intelligence in neurology: opportunities, challenges, and policy implications. J Neurol. 2024, 271:2258-73. 10.1007\/s00415-024-12220-8","journal-title":"J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson O","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021, 27:954-63. 10.1038\/s41591-021-01382-x","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-023-00731-8","article-title":"Connectome-based modelling of neurodegenerative diseases: towards precision medicine and mechanistic insight","volume":"24","author":"Vogel JW","year":"2023","unstructured":"Vogel JW, Corriveau-Lecavalier N, Franzmeier N, et al.. Connectome-based modelling of neurodegenerative diseases: towards precision medicine and mechanistic insight. Nat Rev Neurosci. 2023, 24:620-39. 10.1038\/s41583-023-00731-8","journal-title":"Nat Rev Neurosci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.3533","article-title":"Digital biomarkers for neurodegenerative disease","volume":"82","author":"Erickson CM","year":"2025","unstructured":"Erickson CM, Wexler A, Largent EA. Digital biomarkers for neurodegenerative disease. JAMA Neurol. 2025, 82:5-6. 10.1001\/jamaneurol.2024.3533","journal-title":"JAMA Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.597451","article-title":"Deep Brain Stimulation Initiative: toward innovative technology, new disease indications, and approaches to current and future clinical challenges in neuromodulation therapy","volume":"11","author":"Sui Y","year":"2020","unstructured":"Sui Y, Tian Y, Ko WK, et al.. Deep Brain Stimulation Initiative: toward innovative technology, new disease indications, and approaches to current and future clinical challenges in neuromodulation therapy. Front Neurol. 2020, 11:597451. 10.3389\/fneur.2020.597451","journal-title":"Front Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00426-z","article-title":"Technology of deep brain stimulation: current status and future directions","volume":"17","author":"Krauss JK","year":"2021","unstructured":"Krauss JK, Lipsman N, Aziz T, et al.. Technology of deep brain stimulation: current status and future directions. Nat Rev Neurol. 2021, 17:75-87. 10.1038\/s41582-020-00426-z","journal-title":"Nat Rev Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/futurepharmacol4020020","article-title":"Nanotechnology-driven therapeutic innovations in neurodegenerative disorders: a focus on Alzheimer\u2019s and Parkinson\u2019s disease","volume":"4","author":"Krsek A","year":"2024","unstructured":"Krsek A, Baticic L. Nanotechnology-driven therapeutic innovations in neurodegenerative disorders: a focus on Alzheimer\u2019s and Parkinson\u2019s disease. Future Pharmacol. 2024, 4:352-79. 10.3390\/futurepharmacol4020020","journal-title":"Future Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.hest.2025.09.002","article-title":"Application and future directions of brain-computer interfaces in neurological disorders: technological advances, clinical practices, and challenges","volume":"6","author":"Deng Q","year":"2025","unstructured":"Deng Q, Fu Z, Ma N, Wang B. Application and future directions of brain-computer interfaces in neurological disorders: technological advances, clinical practices, and challenges. Brain Hemorrh. 2025, 6:306-14. 10.1016\/j.hest.2025.09.002","journal-title":"Brain Hemorrh"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2019.1562443","article-title":"Nanotheranostics, a future remedy of neurological disorders","volume":"16","author":"Sharma M","year":"2019","unstructured":"Sharma M, Dube T, Chibh S, Kour A, Mishra J, Panda JJ. Nanotheranostics, a future remedy of neurological disorders. Expert Opin Drug Deliv. 2019, 16:113-28. 10.1080\/17425247.2019.1562443","journal-title":"Expert Opin Drug Deliv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting PF","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME, et al.. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011, 155:529-36. 10.7326\/0003-4819-155-8-201110180-00009","journal-title":"Ann Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-025-03406-2","article-title":"Effect of perioperative intranasal insulin on postoperative delirium in elderly hip fracture patients undergoing general anesthesia: a randomized controlled study","volume":"25","author":"Wang J","year":"2025","unstructured":"Wang J, Dai C, Li H, Wang J, Guan S, Wang Q, Cai N. Effect of perioperative intranasal insulin on postoperative delirium in elderly hip fracture patients undergoing general anesthesia: a randomized controlled study. BMC Anesthesiol. 2025, 25:525. 10.1186\/s12871-025-03406-2","journal-title":"BMC Anesthesiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.122.042200","article-title":"Infarcts in a new territory: insights from the ESCAPE-NA1 trial","volume":"54","author":"Singh N","year":"2023","unstructured":"Singh N, Cimflova P, Ospel JM, et al.. Infarcts in a new territory: insights from the ESCAPE-NA1 trial. Stroke. 2023, 54:1477-83. 10.1161\/STROKEAHA.122.042200","journal-title":"Stroke"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32100541","article-title":"Phase Ib\/II study of pamiparib plus radiation therapy and\/or temozolomide in adult patients with treatment-na\u00efve or recurrent\/refractory glioblastoma","volume":"32","author":"Piotrowski AF","year":"2025","unstructured":"Piotrowski AF, Shih K, Giglio P, et al.. Phase Ib\/II study of pamiparib plus radiation therapy and\/or temozolomide in adult patients with treatment-na\u00efve or recurrent\/refractory glioblastoma. Curr Oncol. 2025, 32:541. 10.3390\/curroncol32100541","journal-title":"Curr Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03774-7","article-title":"Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis","volume":"73","author":"Guo G","year":"2024","unstructured":"Guo G, Zhang Z, Zhang J, et al.. Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis. Cancer Immunol Immunother. 2024, 73:193. 10.1007\/s00262-024-03774-7","journal-title":"Cancer Immunol Immunother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02836-9","article-title":"A multi-cohort study of the hippocampal radiomics model and its associated biological changes in Alzheimer's disease","volume":"14","author":"Xia H","year":"2024","unstructured":"Xia H, Luan X, Bao Z, Zhu Q, Wen C, Wang M, Song W. A multi-cohort study of the hippocampal radiomics model and its associated biological changes in Alzheimer's disease. Transl Psychiatry. 2024, 14:111. 10.1038\/s41398-024-02836-9","journal-title":"Transl Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-00590-6","article-title":"Cell therapy with placenta-derived mesenchymal stem cells for secondary progressive multiple sclerosis patients in a phase 1 clinical trial","volume":"15","author":"Shokati A","year":"2025","unstructured":"Shokati A, Nikbakht M, Sahraian MA, et al.. Cell therapy with placenta-derived mesenchymal stem cells for secondary progressive multiple sclerosis patients in a phase 1 clinical trial. Sci Rep. 2025, 15:16005. 10.1038\/s41598-025-00590-6","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019362","article-title":"Newly diagnosed atrial fibrillation after transient ischemic attack versus minor ischemic stroke in the POINT trial","volume":"10","author":"Kamel H","year":"2021","unstructured":"Kamel H, Farrant M, Easton JD, Sposato LA, Elm JJ, Underwood E, Johnston SC. Newly diagnosed atrial fibrillation after transient ischemic attack versus minor ischemic stroke in the POINT trial. J Am Heart Assoc. 2021, 10:e019362. 10.1161\/JAHA.120.019362","journal-title":"J Am Heart Assoc"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03270-6","article-title":"Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial","volume":"30","author":"Pagano G","year":"2024","unstructured":"Pagano G, Monnet A, Reyes A, et al.. Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024, 30:3669-75. 10.1038\/s41591-024-03270-6","journal-title":"Nat Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s40814-023-01354-7","article-title":"Acceptance and commitment therapy for people living with motor neuron disease: an uncontrolled feasibility study","volume":"9","author":"Gould RL","year":"2023","unstructured":"Gould RL, Rawlinson C, Thompson B, et al.. Acceptance and commitment therapy for people living with motor neuron disease: an uncontrolled feasibility study. Pilot Feasibility Stud. 2023, 9:116. 10.1186\/s40814-023-01354-7","journal-title":"Pilot Feasibility Stud"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251370769","article-title":"OnabotulinumtoxinA for the preventive treatment of episodic migraine: results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial","volume":"45","author":"Pozo-Rosich P","year":"2025","unstructured":"Pozo-Rosich P, Blumenfeld AM, Lipton RB, et al.. OnabotulinumtoxinA for the preventive treatment of episodic migraine: results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial. Cephalalgia. 2025, 45:3331024251370769. 10.1177\/03331024251370769","journal-title":"Cephalalgia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-025-04434-8","article-title":"Effects of PCSK9 inhibitor evolocumab on preventing early neurological deterioration in acute ischemic stroke patients with or without large artery atherosclerosis: a subgroup analysis of a randomized trial","volume":"25","author":"Liu J","year":"2025","unstructured":"Liu J, Li Y, Tian W, et al.. Effects of PCSK9 inhibitor evolocumab on preventing early neurological deterioration in acute ischemic stroke patients with or without large artery atherosclerosis: a subgroup analysis of a randomized trial. BMC Neurol. 2025, 25:431. 10.1186\/s12883-025-04434-8","journal-title":"BMC Neurol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2174\/0113816128284824240328071911","article-title":"Revolutionizing neurological disorder treatment: integrating innovations in pharmaceutical interventions and advanced therapeutic technologies","volume":"30","author":"Arora R","year":"2024","unstructured":"Arora R, Baldi A. Revolutionizing neurological disorder treatment: integrating innovations in pharmaceutical interventions and advanced therapeutic technologies. Curr Pharm Des. 2024, 30:1459-71. 10.2174\/0113816128284824240328071911","journal-title":"Curr Pharm Des"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021340","article-title":"Mechanistic insights, treatment paradigms, and clinical progress in neurological disorders: current and future prospects","volume":"24","author":"Alkahtani S","year":"2023","unstructured":"Alkahtani S, Al-Johani NS, Alarifi S. Mechanistic insights, treatment paradigms, and clinical progress in neurological disorders: current and future prospects. Int J Mol Sci. 2023, 24:1340. 10.3390\/ijms24021340","journal-title":"Int J Mol Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/21691401.2024.2304814","article-title":"Advances in nanotechnology-assisted photodynamic therapy for neurological disorders: a comprehensive review","volume":"52","author":"Nasir A","year":"2024","unstructured":"Nasir A, Rehman MU, Khan T, et al.. Advances in nanotechnology-assisted photodynamic therapy for neurological disorders: a comprehensive review. Artif Cells Nanomed Biotechnol. 2024, 52:84-103. 10.1080\/21691401.2024.2304814","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1485799","article-title":"Harnessing artificial intelligence for the diagnosis and treatment of neurological emergencies: a comprehensive review of recent advances and future directions","volume":"15","author":"AbuAlrob MA","year":"2024","unstructured":"AbuAlrob MA, Mesraoua B. Harnessing artificial intelligence for the diagnosis and treatment of neurological emergencies: a comprehensive review of recent advances and future directions. Front Neurol. 2024, 15:1485799. 10.3389\/fneur.2024.1485799","journal-title":"Front Neurol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13051045","article-title":"Navigating neurodegeneration: integrating biomarkers, neuroinflammation, and imaging in Parkinson\u2019s, Alzheimer\u2019s, and motor neuron disorders","volume":"13","author":"Tanaka M","year":"2025","unstructured":"Tanaka M, Battaglia S, Liloia D. Navigating neurodegeneration: integrating biomarkers, neuroinflammation, and imaging in Parkinson\u2019s, Alzheimer\u2019s, and motor neuron disorders. Biomedicines. 2025, 13:1045. 10.3390\/biomedicines13051045","journal-title":"Biomedicines"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2019.1630415","article-title":"Gene therapy for neurological disorders: challenges and recent advancements","volume":"28","author":"Pena SA","year":"2020","unstructured":"Pena SA, Iyengar R, Eshraghi RS, et al.. Gene therapy for neurological disorders: challenges and recent advancements. J Drug Target. 2020, 28:111-28. 10.1080\/1061186X.2019.1630415","journal-title":"J Drug Target"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/505168-a-systematic-literature-review-of-emerging-advances-in-neurological-disorders-diagnostic-innovations-therapeutic-strategies-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:06:10Z","timestamp":1783425970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/505168-a-systematic-literature-review-of-emerging-advances-in-neurological-disorders-diagnostic-innovations-therapeutic-strategies-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.112202","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,7]]}}}